Press Release

North America ACE Inhibitors Market to Grow with a CAGR of 5.25% through 2029

Growing prevalence of cardiovascular diseases is expected to drive the North America ACE Inhibitors Market in the forecast period 2025-2029


According to TechSci Research report, “North America ACE Inhibitors Market – By Country, Competition, Forecast & Opportunities, 2029F”, the North America ACE Inhibitors Market stood at USD 2.18 Billion in 2023 and is anticipated to grow with a CAGR of 5.25% in the forecast periodAngiotensin-converting enzyme (ACE) inhibitors have emerged as essential agents in the realm of cardiovascular drug therapy. These medications, designed to relax blood vessels and lower blood pressure, are crucial in managing a variety of cardiovascular conditions. The significance of the ACE inhibitors market is particularly pronounced within the pharmaceutical sector of North America, where cardiovascular diseases (CVDs) are on the rise. The escalating incidence of hypertension, coronary artery disease, and heart failure has amplified the demand for effective treatments, positioning ACE inhibitors as fundamental components in addressing cardiovascular health issues. The role of ACE inhibitors in cardiovascular therapy cannot be overstated. These drugs function by inhibiting the angiotensin-converting enzyme, which is pivotal in the renin-angiotensin-aldosterone system (RAAS). This inhibition leads to decreased production of angiotensin II, a potent vasoconstrictor, thereby promoting vasodilation and reducing blood pressure. Moreover, ACE inhibitors facilitate the excretion of sodium and water, which further aids in lowering blood pressure and reducing the workload on the heart. This mechanism of action makes ACE inhibitors highly effective in treating hypertension, one of the most prevalent cardiovascular conditions globally.

Hypertension, often termed the "silent killer," affects millions of individuals worldwide and is a major risk factor for more severe cardiovascular events such as strokes and myocardial infarctions. The growing prevalence of hypertension, especially in North America, underscores the necessity for reliable antihypertensive medications. ACE inhibitors, with their proven efficacy, have become a mainstay in the management of hypertension. Their ability to improve endothelial function, reduce arterial stiffness, and lower the risk of adverse cardiovascular outcomes makes them invaluable in the therapeutic arsenal against high blood pressure. Coronary artery disease (CAD) is another area where ACE inhibitors play a critical role. CAD, characterized by the narrowing of coronary arteries due to plaque buildup, can lead to angina and myocardial infarctions. By promoting vasodilation and enhancing blood flow, ACE inhibitors help alleviate the symptoms of angina and reduce the frequency of cardiac events. Additionally, their ability to stabilize atherosclerotic plaques and prevent further progression of the disease makes them a cornerstone in the long-term management of CAD. This is particularly important in North America, where lifestyle factors such as poor diet, lack of exercise, and high stress levels contribute to the high incidence of CAD.

Heart failure is a debilitating condition that significantly impairs quality of life and has high mortality rates. The therapeutic benefits of ACE inhibitors extend to heart failure management, where they have been shown to improve survival rates and reduce hospitalizations. By lowering blood pressure and reducing fluid retention, ACE inhibitors decrease the workload on the heart, allowing it to function more efficiently. They also help prevent the remodeling of heart tissue, which can exacerbate heart failure. In a region like North America, where the aging population is growing and the incidence of heart failure is rising, the role of ACE inhibitors is critical in improving patient outcomes and reducing healthcare costs.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "North America ACE Inhibitors Market

The North America ACE Inhibitors Market is a vital segment of the pharmaceutical industry, addressing cardiovascular conditions like hypertension and heart failure. With a growing burden of cardiovascular diseases in the region, ACE inhibitors play a crucial role in managing and treating these conditions. Factors such as the aging population, lifestyle changes, and the prevalence of comorbidities contribute to the market's growth. Technological advancements, research and development activities, and strategic collaborations further drive market expansion. As demand for effective cardiovascular therapies rises, the North America ACE Inhibitors Market continues to evolve to meet the healthcare needs of the population.

The North America ACE Inhibitors Market is segmented into type, drug, dosage form, application, end user, region, and company.

Based on drugs, Ramipril stands out as dominant in the North America market. Its popularity stems from several factors, including its proven efficacy in managing hypertension and heart failure, favorable safety profile, and widespread use in clinical practice. Ramipril offers once-daily dosing convenience, enhancing patient compliance. Clinical studies have demonstrated its effectiveness in reducing the risk of cardiovascular events, making it a preferred choice for many healthcare providers. Its long-standing presence in the market, coupled with extensive research and positive patient outcomes, solidifies Ramipril's position as a leading ACE inhibitor in North America.

Based on application, Hypertension emerges as the dominant condition among Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, and others in the ACE Inhibitors market. The prevalence of hypertension is notably high, affecting a significant portion of the population. ACE inhibitors are widely recognized as first-line therapy for hypertension due to their efficacy in reducing blood pressure and preventing cardiovascular complications. Hypertension often coexists with other cardiovascular conditions, further driving the demand for ACE inhibitors. Given their established efficacy and widespread use, ACE inhibitors, including Ramipril and Enalapril, remain the preferred choice for managing hypertension, solidifying their dominance in the market.

Based on end user, Hospitals emerge as the dominant distribution channel among Hospitals, Online Drug Stores, and others in the ACE Inhibitors market. Hospitals serve as primary points of care for patients with cardiovascular conditions, facilitating direct access to ACE inhibitors upon prescription by healthcare professionals. Hospitals typically stock a wide range of pharmaceuticals, including ACE inhibitors, ensuring availability for patients requiring immediate treatment. While online drug stores offer convenience and accessibility, hospitals maintain prominence due to their established infrastructure, expertise in cardiovascular care, and ability to provide comprehensive treatment solutions, consolidating their position as the dominant distribution channel for ACE inhibitors. 

Major companies operating in North America ACE Inhibitors Market are:

  • Pfizer Inc
  • Novartis AG
  • Johnson & Johnson
  • Merck KGaA
  • Sanofi S.A
  • Bayer AG
  • United Therapeutics Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals Company Ltd.

Download Free Sample Report

Customers can also request 10% free customization on this report.

“The ACE Inhibitors Market holds a promising future, driven by advancements in healthcare, escalating cardiovascular disease burdens, and evolving treatment strategies. Ongoing research and development efforts aim to introduce more targeted and innovative ACE inhibitors, offering patients improved therapeutic options with fewer side effects. Personalized medicine will gain prominence, ensuring tailored treatments for individual patients. The adoption of telemedicine and digital healthcare will improve accessibility and treatment adherence. With the aging population and increasing awareness of hypertension, the demand for ACE inhibitors is projected to remain robust. Pharmaceutical companies have ample opportunities to innovate and address the evolving needs of patients in the market's future” said Mr. Karan Chechi, Research Director of  TechSci Research, a research-based management consulting firm.

North America ACE Inhibitors Market By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents), By Drugs (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others), By Dosage Form (Oral Tablets, Oral Solutions), By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others), By End user (Hospitals, Online Drug Stores, Others), By Country, Competition, Forecast and Opportunities, , 2019-2029F”, has evaluated the future growth potential of North America ACE Inhibitors Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in North America ACE Inhibitors Market.


TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               


Relevant News